Liguria has administrated 1,400 doses of antibodies against RSV

Approximately 1400 doses of the monoclonal antibody ‘Nirsevimab’ have been administered in Liguria for immunization against the human respiratory syncytial virus (RSV), the cause of bronchiolitis and pneumonia in children. Currently, around 3000 doses are still available and will be administered in the coming weeks to newborns and children born from 27 July 2024. The administration of the drug can be carried out directly in the birth centers before the child is discharged, in the clinics and hygiene institutes of the local health authorities, or the offices of paediatricians of free choice. The regional health councilor, Massimo Nicolò, declared himself satisfied with the level of adherence to the vaccination campaign by families, who demonstrate that they understand the danger of RSV, especially for younger patients with cardiac or respiratory problems developed in the early two years. According to health sources, adherence to therapy among newborns is around 80%.